Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Switch study from NNRTI + FTC/TDF to EVG/COBI/FTC/TDF in virologically suppressed HIV-1 infection
2011-004963-56Phase 3Completed
- Sponsor
- Gilead Sciences
- Start
- Nov 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of emtricitabine + elvitegravir + cobicistat + tenofovir disoproxil in Human immunodeficiency virus infection type 1 (2 arms), sponsored by Gilead Sciences. Primary endpoint: Proportion of subjects with HIV-1 RNA < 50 copies/mL at Week 48. Started Nov 2011; status: completed.
02
Drugs
emtricitabine + elvitegravir + cobicistat + tenofovir disoproxil
03
Conditions
Human immunodeficiency virus infection type 1
Beyond the preview
Go deeper on 2011-004963-56.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-004963-56.